Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Pfenex enters strategic agreement with Boehringer Ingelheim for use of Expression Technology

Pfenex Inc., an industry leader in protein expression through the Pfenex Expression Technology platform and Boehringer Ingelheim International GmbH, a leading pharmaceutical company and global leader in biopharmaceutical contract development and manufacture, announced today that they have entered into a strategic agreement.

16 Feb 2011

Aeolus receives BARDA contract for AEOL 10150 drug development against ARS

Aeolus Pharmaceuticals, a biopharmaceutical company developing a new class of broad spectrum catalytic antioxidant compounds that reduce oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure, today announced that the Biomedical Advanced Research and Development Authority, part of the Department of Health and Human Services, has awarded Aeolus a contract for the advanced development of AEOL 10150 as a medical countermeasure against the pulmonary sub-syndrome of acute radiation syndrome.

16 Feb 2011

Almac's Director plans to speak on adaptive trial designs at CTS Europe conference

The Almac Group announced today that Graham Nicholls, Director of Biostatistics for Almac's Clinical Technologies business unit, will be speaking at the Clinical Trial Supply Europe conference held in Barcelona, Spain, 22-23 February 2011.

15 Feb 2011

FDA provides less-burdensome path to market certain hardware, software used with medical devices

Today, the FDA announced a final rule that provides a less-burdensome path to market for certain hardware and software products used with medical devices. The rule classifies these products, known as Medical Device Data Systems or MDDS, as Class I or low-risk devices, making them exempt from premarket review but still subject to quality standards.

15 Feb 2011

Kamada reports positive interim results from Alpha-Antitrypsin Phase 2-3 trial to treat Alpha-1 deficiency

Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it received the interim report of its phase 2-3 trial to treat Alpha-1 deficiency with its flag product, Alpha-Antitrypsin, delivered by inhalation.

14 Feb 2011

Microbix first quarter revenues decrease 34% to $812,694

Microbix Biosystems Inc., a biotechnology company commercializing novel technologies for influenza vaccine manufacturing and livestock semen sexing, in addition to a core business of virology products, today reported financial results for the first quarter of fiscal 2011. For the quarter ended December 31, 2010, Microbix reported revenues of $812,694, a 34% decrease from $1,226,538 for the same period in 2009.

14 Feb 2011

Tianyin Pharmaceutical's second quarter revenue increases 69.6% to $25.3 million

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, announced the financial results for the second quarter of Fiscal Year 2011.

14 Feb 2011

BioTime to merge Glycosan with OrthoCyte

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has signed a definitive agreement to merge Utah-based Glycosan BioSystems, Inc. (Glycosan) with BioTime's wholly-owned subsidiary, OrthoCyte Corporation. The acquisition is expected to close by March 18, 2011.

14 Feb 2011

Bohai second quarter net revenues increase 32% to $22.2 million

Bohai Pharmaceuticals Group, Inc., a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today reported record financial results for its second quarter of fiscal 2011 ended December 31, 2010.

14 Feb 2011

ArthroCare fourth quarter total revenue increases to $92.6 million

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced its financial results for the fourth quarter and year ended December 31, 2010.

14 Feb 2011

Elite third quarter consolidated revenues increase 34% to $1.2 million

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to developing and commercializing oral controlled release product formulations, announced results for the fiscal third quarter ended December 31, 2011.

14 Feb 2011

Nine new Research Units to be established by DFG

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish nine new Research Units. This decision was taken by the DFG's Senate at its February session in Bonn. The new groups are intended to provide researchers with the opportunity to address current and urgent issues in their fields and to develop new research strategies.

14 Feb 2011

Advocates call for follow-through on decade-old pledge to remove tariffs on malaria treatments, prophylactics in Africa

"Malaria prevention advocates say many lives can be saved by removing taxes and tariffs from essential commodities used to fight the disease," VOA News reports. A decade ago, African leaders promised to remove tariffs on products used to fight malaria, but only six countries have actually done so, according to the Malaria Taxes and Tariffs Advocacy Project, which held a meeting in Geneva on Wednesday, Reuters reports.

14 Feb 2011

More people sick with salmonella from custard pastries

According to South Australia Health authorities, 13 more people have fallen ill with salmonella that spread via three types of custard-filled pastries made in Adelaide. This brings the total number of ill people to 74 with 29 admitted to hospital with salmonella typhimurium phage type 9 infection. The custard-filled products from Vili’s and St George Cakes and Gelati were recalled after being associated with the salmonella outbreak.

13 Feb 2011

Dyadic issued seventh U.S. patent

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has been issued U.S. Patent No. 7,883,872 entitled, Construction of Highly Efficient Cellulase Compositions for Enzymatic Hydrolysis of Cellulose, by the United States Patent and Trademark Office ("USPTO").

11 Feb 2011

Sorin's 2010 consolidated revenues increase 4.9% to € 745.8 million

The Board of Directors of Sorin S.p.A. meeting today under the chairmanship of Rosario Bifulco reviewed the fourth quarter 2010 and the preliminary 2010 consolidated results.

11 Feb 2011

First 7 stem cell lines grown at UMMS Human Stem Cell Bank ready for global distribution

The first seven stem cell lines grown and banked at the University of Massachusetts Medical School's Human Stem Cell Bank are ready for worldwide distribution to researchers working on discovering new therapeutic treatments for diseases such as cancer, juvenile diabetes, Alzheimer's and Parkinson's, among others.

11 Feb 2011

Viewpoints: Sebelius on empowering states; NY Times on insurance mandate; WSJ on 'next repeal target'

As governor of Kansas, I saw up close the urgent need for health-care reform. I heard it when factory owners told me their biggest concern was not manufacturing costs but rising insurance premiums, and when families said they felt like hostages to insurance companies that could deny or cancel coverage with little accountability.

11 Feb 2011

Bradmer Pharmaceuticals records net loss of $117,000 for fourth quarter of 2010

Bradmer Pharmaceuticals Inc. today announced its 2010 fourth quarter and fiscal year operational and financial results.

10 Feb 2011

Orthovita receives 510(k) clearance to market Vitoss BA Bimodal Bone Graft Substitute

Orthovita, Inc., an orthobiologics and biosurgery company, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration to market Vitoss BA Bimodal Bone Graft Substitute as a non-structural bone void filler for use in the extremities, pelvis and posterolateral spine.

10 Feb 2011

Manufacturing News and Research

Further Reading

Pfenex enters strategic agreement with Boehringer Ingelheim for use of Expression Technology

Aeolus receives BARDA contract for AEOL 10150 drug development against ARS

Almac's Director plans to speak on adaptive trial designs at CTS Europe conference

FDA provides less-burdensome path to market certain hardware, software used with medical devices

Kamada reports positive interim results from Alpha-Antitrypsin Phase 2-3 trial to treat Alpha-1 deficiency

Microbix first quarter revenues decrease 34% to $812,694

Tianyin Pharmaceutical's second quarter revenue increases 69.6% to $25.3 million

BioTime to merge Glycosan with OrthoCyte

Bohai second quarter net revenues increase 32% to $22.2 million

ArthroCare fourth quarter total revenue increases to $92.6 million

Elite third quarter consolidated revenues increase 34% to $1.2 million

Nine new Research Units to be established by DFG

Advocates call for follow-through on decade-old pledge to remove tariffs on malaria treatments, prophylactics in Africa

More people sick with salmonella from custard pastries

Dyadic issued seventh U.S. patent

Sorin's 2010 consolidated revenues increase 4.9% to € 745.8 million

First 7 stem cell lines grown at UMMS Human Stem Cell Bank ready for global distribution

Viewpoints: Sebelius on empowering states; NY Times on insurance mandate; WSJ on 'next repeal target'

Bradmer Pharmaceuticals records net loss of $117,000 for fourth quarter of 2010

Orthovita receives 510(k) clearance to market Vitoss BA Bimodal Bone Graft Substitute

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy